Global Leader in Anti-Infective Treatments Xellia Pharmaceuticals is a renowned global leader in providing anti-infective treatments for serious and life-threatening conditions. This expertise presents a significant sales opportunity for targeting markets where there is a high demand for such critical care therapies.

Recent Expansion into Cleveland, Ohio With the recent expansion of facilities to Cleveland, Ohio, Xellia Pharmaceuticals has created a new market presence in the United States. This expansion offers a strategic opportunity for sales development representatives to capitalize on the commercial production and distribution capabilities in this region.

New Chief Executive Officer Appointment The appointment of a new Chief Executive Officer, Michael Kocher, brings fresh leadership to Xellia Pharmaceuticals. Leveraging this change in leadership can serve as an entry point for sales professionals to establish new relationships and explore potential collaborations under the guidance of the new CEO.

Acquisition of Assets from Hikma Pharmaceuticals Through the acquisition of assets from Hikma Pharmaceuticals, including the closed facility in Bedford, OH, Xellia Pharmaceuticals has expanded its operational capacity and product portfolio. Sales development representatives can capitalize on this acquisition to explore new sales channels and partnerships resulting from this strategic move.

Specialty Pharmaceutical Company with Extensive Heritage As a specialty pharmaceutical company with over 120 years of industry experience, Xellia Pharmaceuticals has a strong foundation in developing, manufacturing, and commercializing products. This rich heritage and expertise provide a unique sales opportunity to engage with partners and customers looking for reliable and established pharmaceutical providers.